A Phase II Study of Paclitaxel and Carboplatin with a Biweekly Schedule in Patients with Epithelial Ovarian Cancer: Gynecologic Cancer Network Trial

作者：Yoneyama Koichi^*; Konishe Hideki; Yahata Tetsuro; Fujita Kazuyuki; Aoki Yoichi; Doi Daisuke; Matsushima Takashi; Kodama Shoji; Honma Shigeru; Kato Hisamori; Nakayama Hiroki; Kamoi Seiryu; Asakura Hirobumi; Takeshita Toshiyuki; Tanaka Kenichi

来源：Nippon Medical School Journal, 2014, 81(1): 28-34.

DOI：10.1272/jnms.81.28

• phase II study
• paclitaxel
• carboplatin
• biweekly schedule
• ovarian cancer

Aim: The objective of this multicenter phase II study was to evaluate the effects of biweekly paclitaxel and carboplatin combination chemotherapy on response rate and toxicities in patients with epithelial ovarian cancer. %26lt;br%26gt;Patients and Methods: Patients with International Federation of Gynecology and Obstetrics stage II to IV ovarian cancer received paclitaxel at a dose of 120 mg/m(2) and carboplatin at an area under the curve of 3 mg/mL per minute every 2 weeks for 8 or more cycles. Inclusion criteria included an Eastern Cooperative Oncology Group performance status of 0 to 2 and no previous chemotherapy. Informed consent was obtained from each patient before the start of treatment. %26lt;br%26gt;Results: From March 2003 through July 2009, 42 patients from 5 institutions were eligible to be evaluated for response and toxicity. The median age was 60.5 years (age range, 34-81 years). The International Federation of Gynecology and Obstetrics stage was stage II in 3 patients, stage III in 31 patients, and stage IV in 8 patients. The response rate was 66.7% (95% confidence interval: 50.5 %-80.4%). Sixty-nine percent (29 of 42) of patients received 8 or more cycles of chemotherapy. The median progression-free survival was 18.5 months, and overall survival was 59.1 months. The most common grade 3 or 4 hematological toxicity was neutropenia (61.0%). No patients had grade 3 or 4 thrombocytopenia. The most common grade 3 nonhematological toxicities were neuropathy (4.9%) and nausea (2.4%). %26lt;br%26gt;Conclusion: Paclitaxel combined with carboplatin using a biweekly schedule is a safe and effective chemotherapy regimen for patients with epithelial ovarian cancer. Our results suggest that a biweekly schedule is well tolerated and is less toxic than a triweekly schedule.

• 出版日期2014-2